Crossmark

Evaluation of safety and affection of variable duration of dual antiplatelet therapy using aspirin plus ticagrelor after successful percutaneous coronary intervention for diabetic patients with acute coronary syndrome

Crossref DOI link: https://doi.org/10.1186/s12872-026-05708-w

Published Online: 2026-03-27

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Ibrahim, Nour Eldeen Mahmoud Shabaan

Zaki, Mohamed Tarek Mounir

Abdel Magid, Khaled Ahmed Fouad

Fouad, Khaled Ahmed

Iskandar, Mina Magued Abdalla
Funding

Funding for this research was provided by:

Ain Shams University
License Information

Text and Data Mining valid from 2026-03-27

Version of Record valid from 2026-04-09
More Information

Article History

Received: 26 November 2025

Accepted: 4 March 2026

First Online: 27 March 2026

Declarations

:

: The study protocol was approved by the Scientific and Ethical Committee of the Faculty of Medicine, Ain Shams University (Approval code: MD 307 /2022, Approval date: December 2022). All patients were informed about the study and provided consents.The authors declare that all procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below